{"filings":[{"id":95094,"accession_number":"0001171843-26-003005","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics reports tovecimig Phase 2/3 BTC data with significant PFS benefit; BLA planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tovecimig + paclitaxel: ORR 17.1% vs 5.3% (p=0.031); PFS 4.7 vs 2.6 months (HR=0.44, p<0.0001); OS crossover benefit.","Company plans FDA meeting then BLA submission for tovecimig in second-line BTC by end of 2026.","CTX-8371 cohort expansions in TNBC, NSCLC, HL initiated; dose-escalation data at ASCO 2026 poster.","CTX-10726 Phase 1 study initiated; initial clinical data expected in Q4 2026.","Cash and marketable securities $195M at Q1 2026; net loss $18.3M ($0.10/share); cash runway into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95093,"accession_number":"0001171843-26-002720","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Compass reports tovecimig hits PFS endpoint in BTC Ph2/3; plans BLA submission","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tovecimig + paclitaxel met key secondary PFS endpoint: median 4.7 vs 2.6 months (HR=0.44, p<0.0001).","Primary ORR (previously announced) was 17.1% vs 5.3% (p=0.031); one complete response in tovecimig arm.","OS endpoint not met due to 54% crossover; ITT OS 8.9 vs 9.4 months (HR=1.05, p=0.78).","Crossover patients had median OS 12.8 months vs 6.1 months for non-crossover (HR=0.54, p=0.04).","Company intends to meet with FDA to discuss data in advance of a planned BLA submission for second-line BTC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107921,"accession_number":"0001171843-26-001336","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics reports 2025 net loss of $66.5M; tovecimig PFS/OS data due in April","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $66.5M ($0.42/share) vs $49.4M ($0.36/share) in 2024; R&D spend up 32% to $56.0M.","Cash and marketable securities $209M as of Dec 31, 2025; expected runway into 2028.","Tovecimig COMPANION-002 PFS/OS analyses expected in April 2026 after reaching 80% OS events.","CTX-8371 expansion cohorts enrolling in TNBC and NSCLC; initial data expected Q2 2026.","CTX-10726 IND cleared; Phase 1 enrolling in Q1 2026; Bing Gong promoted to CSO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107920,"accession_number":"0001171843-26-000083","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Compass Therapeutics reports $209M cash, tovecimig PFS/OS data on track Q1 2026; appoints CCO and CMO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and marketable securities estimated at $209M as of Dec 31, 2025; cash runway into 2028.","Analyses of PFS and OS in tovecimig Phase 2/3 BTC trial expected late Q1 2026; BLA preparation underway.","CTX-8371: third confirmed response in Hodgkin Lymphoma; expansions open in TNBC and NSCLC.","Appointed Arjun Prasad as CCO and Cynthia Sirard as CMO effective January 2026.","CTX-10726 Phase 1 initiation expected Q1 2026 with initial data in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124335,"accession_number":"0001171843-25-007004","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics Q3 2025 net loss $14.3M; cash $220M; tovecimig OS/PFS data late Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss Q3 2025 $14.3M ($0.08/share) vs $10.5M ($0.08) Q3 2024; nine-month loss $50.8M ($0.34).","Cash and marketable securities $220M as of Sep 30, 2025, up from $127M Dec 2024; cash runway through 2028.","Tovecimig: OS and PFS data from Phase 2/3 COMPANION-002 in BTC expected late Q1 2026.","CTX-8371 Phase 1 fully enrolled, no DLTs; cohort expansions in NSCLC and TNBC start Q4 2025; data H1 2026.","CTX-10726 IND filing on track for Q4 2025; initial Phase 1 data expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141013,"accession_number":"0001193125-25-179958","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Compass Therapeutics prices $120M upsized public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced upsized $120M offering: 33.29M shares at $3.00/share and 6.71M pre-funded warrants at $2.9999 each.","Net proceeds estimated at $112.5M (base), up to $129.5M if underwriters' 30-day option for 6M additional shares is exercised.","Proceeds to fund commercial readiness, R&D of product candidates, and general corporate purposes.","Cash and equivalents expected to fund operations into 2028.","Jefferies, Piper Sandler, and Guggenheim Securities are joint bookrunners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141012,"accession_number":"0001171843-25-005260","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Compass Q2 net loss $19.9M; CTX-8371 shows deep responses; tovecimig OS readout moves to Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2025 $19.9M ($0.14/share) vs $13.1M ($0.10/share) in Q2 2024; R&D expenses rose 47% to $16.4M.","Tovecimig Ph2/3 BTC trial met primary endpoint (ORR 17.1% vs 5.3%, p=0.031); OS analysis delayed to Q1 2026 due to fewer deaths.","CTX-8371 Ph1: confirmed PR in NSCLC with 100% target lesion reduction and TNBC with >90% reduction; expansion cohorts planned Q4 2025.","CTX-10726 (PD-1 x VEGF-A) showed superior PD-1 inhibition and tumor control vs ivonescimab preclinically; IND filing on track for Q4 2025.","Cash and marketable securities $101M as of June 30, 2025; expected cash runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158787,"accession_number":"0001171843-25-003868","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Compass Therapeutics annual meeting elects three directors, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carl L. Gordon, Philip J. Ferneau, and James P. Boylan elected as Class II directors with 80.7M, 58.3M, and 83.6M votes for, respectively.","Ratification of CohnReznick LLP as auditor for FY2025 approved with 114.3M for, 28,647 against, 22,788 abstain.","Broker non-votes of 29,432,541 on director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158786,"accession_number":"0001171843-25-002952","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics: Tovecimig meets primary endpoint in BTC trial; Q1 net loss $16.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tovecimig + paclitaxel achieved 17.1% ORR (incl. 1 complete response) vs 5.3% for paclitaxel alone (p=0.031) in Phase 2/3 BTC study.","Secondary endpoints PFS, OS, DoR analyses expected Q4 2025; pre-specified event count not yet met.","Q1 2025 net loss $16.6M ($0.12/sh), R&D $13.1M (+37% YoY), cash $113M providing runway into 2027.","CTX-10726 (PD-1 x VEGF-A) pre-IND meeting completed; IND filing expected Q4 2025.","CTX-8371 Phase 1 dose-escalation advanced to 4th cohort with no DLTs; preliminary data H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158785,"accession_number":"0001171843-25-001900","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tovecimig meets primary endpoint in Phase 2/3 BTC trial: 17.1% ORR vs 5.3% (p=0.031)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR 17.1% for tovecimig+paclitaxel (19/111) vs 5.3% for paclitaxel alone (3/57), p=0.031, statistically significant.","One complete response in combo arm; progressive disease rate 16.2% vs 42.1%.","Secondary endpoints (PFS, OS, DoR) not yet mature; expected Q4 2025 after 80% event threshold.","Safety consistent with prior studies; DMC recommended continuation after four reviews.","BTC affects ~23,000 US patients annually; ~85% lack approved second-line targeted therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177190,"accession_number":"0001171843-25-001105","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics reports FY2024 net loss of $49.4M; tovecimig data expected end Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $49.4M ($0.36/shr) vs $42.5M ($0.33) in 2023; R&D expense $42.3M (+11%).","Cash and marketable securities $127M, down from $152M; cash runway into 2027.","Top-line data from COMPANION-002 (tovecimig in BTC) on track for end of Q1 2025.","Phase 2 trials for tovecimig in DLL4+ CRC and CTX-471 in NCAM+ tumors expected mid-2025.","CTX-10726 IND filing expected year-end 2025; CTX-8371 Phase 1 third cohort enrolled, no DLTs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":850000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177189,"accession_number":"0001171843-25-000116","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Compass Therapeutics provides pipeline update; cash at $127M, tovecimig data Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estimated $127M cash at YE 2024; cash runway expected into Q1 2027.","Top-line Phase 2/3 data for tovecimig (CTX-009) in BTC expected end of Q1 2025.","New drug candidate CTX-10726 (PD-1 x VEGF-A bispecific) advancing; IND submission targeted by YE 2025.","Third dosing cohort fully enrolled for CTX-8371 Phase 1; preliminary data H2 2025.","Two Phase 2 biomarker trials planned for mid-2025: tovecimig in DLL4+ CRC and CTX-471 in NCAM/CD56+ tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193967,"accession_number":"0001171843-24-006847","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Compass Therapeutics appoints Barry Shin as CFO; Neil Lerner as PAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Barry Shin named CFO effective Dec 9, 2024; base salary $475K, target bonus 45%, sign-on $50K, and equity grants of 800K shares total.","Neil Lerner appointed principal accounting officer; he was VP of Finance since November 2020.","Shin replaces Thomas Schuetz as principal financial officer; Schuetz remains CEO.","Press release highlights 2025 catalysts: topline data for CTX-009 expected in Q1 2025.","Shin previously served as CFO/COO at Trevena and held investment banking roles at Mizuho, Guggenheim, and Piper Sandler."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193966,"accession_number":"0001171843-24-006247","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics Q3 2024 net loss $10.5M ($0.08/share); cash $135M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.5M vs $10.0M in Q3 2023; diluted EPS $0.08 unchanged.","Cash and marketable securities $135M as of Sep 30, 2024; runway into Q1 2027.","Phase 2/3 CTX-009 BTC trial fully enrolled; top-line data expected end of Q1 2025.","CTX-009 Phase 2 in DLL4-positive CRC second-line planned for mid-2025.","CTX-471 Phase 2 trial in NCAM-expressing tumors planned for mid-2025 based on biomarker data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":850000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210290,"accession_number":"0001171843-24-004669","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics Q2 net loss $13.1M; CTX-009 BTC trial enrollment completed, top-line data Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.1M ($0.10 per share) for Q2 2024 vs $11.3M loss in Q2 2023.","Cash and marketable securities $146M as of June 30, 2024; cash runway into Q1 2027.","Completed enrollment (n=150) in COMPANION-002 Phase 2/3 trial of CTX-009 in BTC; top-line data expected Q1 2025.","Stage 1 of COMPANION-003 in CRC showed ORR 5%, median PFS 3.9 months, median OS 10.2 months; designing second-line DLL4+ study.","Discontinuing CTX-471 + KEYTRUDA combo due to cytokine suppression; planning Phase 2 monotherapy with new biomarker."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":850000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228599,"accession_number":"0001171843-24-003463","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Compass Therapeutics shareholders elect Chiniara and Gray, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ellen V. Chiniara received 76,766,213 for and 23,754,485 withheld as director.","Mary Ann Gray received 100,051,792 for and 468,906 withheld as director.","Broker non-votes for director proposals were 17,705,143.","Ratification of CohnReznick as auditor passed 118,180,952 for, 13,785 against, 31,104 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228598,"accession_number":"0001171843-24-003129","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Compass Therapeutics CEO Vered Bisker-Leib resigns; Thomas Schuetz appointed CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vered Bisker-Leib, PhD, MBA resigned as CEO and board member effective May 28, 2024, not due to any disagreement.","Thomas Schuetz, MD, PhD (President of R&D, Vice Chair) appointed President and CEO, and Principal Executive/Financial/Accounting Officer.","Separation agreement: 18 months base salary, up to 18 months COBRA reimbursement, release of claims.","Consulting agreement: 15 months at $45,000 annual fee; outstanding equity continues vesting during consultancy.","Schuetz previously served as CEO; returns to role; Board of Directors reduced to seven members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228597,"accession_number":"0001171843-24-002784","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics Q1 net loss $10.8M; cash $156.3M; FDA Fast Track for CTX-009","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.8M ($0.08/share) vs $7.8M ($0.06) in Q1 2023; R&D expenses rose to $9.5M.","Cash and marketable securities $156.3M at March 31, 2024; cash runway into late 2026.","FDA Fast Track for CTX-009 in BTC; COMPANION-002 enrollment to complete mid-2024, data Q1 2025.","Stage 1 of COMPANION-003 (CRC) enrollment complete; top-line data expected by mid-2024.","CTX-8371 first patient dosed in April 2024; Phase 2 planned for CTX-471 in melanoma with biomarker."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228596,"accession_number":"0001171843-24-002220","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA grants Fast Track Designation for Compass's CTX-009 in biliary tract cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Fast Track Designation for CTX-009 (bispecific DLL4/VEGF-A antibody) + paclitaxel in previously treated metastatic/locally advanced biliary tract cancer.","Phase 2 data showed ORR 37.5% (9/24), median PFS 9.4 months, median OS 12.5 months.","Enrollment in Phase 2/3 COMPANION-002 study expected to complete mid-2024; top-line data by year-end 2024.","Co-founder Thomas Schuetz highlighted large unmet need with current single-digit response rates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247247,"accession_number":"0001171843-24-001515","cik":1738021,"company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Therapeutics reports FY2023 net loss of $42.5M; CTX-009 data expected by end 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.5M ($0.33/share) vs $39.2M loss in 2022; R&D expenses rose 27% to $38.1M.","Cash and marketable securities $152.5M at Dec 31, 2023; runway into mid-2026.","CTX-009 Phase 2/3 BTC study (COMPANION-002) enrollment ongoing; top-line data expected year-end 2024.","CTX-009 Phase 2 CRC study (COMPANION-003) Stage 1 enrollment complete; top-line data mid-2024.","CTX-471 Phase 2 monotherapy planning underway for melanoma with novel biomarker; combination arm with KEYTRUDA enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":414202215.5947136,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}